215 related articles for article (PubMed ID: 36757621)
1. Emerging glyco-risk prediction model to forecast response to immune checkpoint inhibitors in colorectal cancer.
Qiu P; Chen X; Xiao C; Zhang M; Wang H; Wang C; Li D; Liu J; Chen Y; Liu L; Zhao Q
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6411-6434. PubMed ID: 36757621
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.
Lv W; Yu H; Han M; Tan Y; Wu M; Zhang J; Wu Y; Zhang Q
Front Immunol; 2022; 13():830158. PubMed ID: 35444644
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
[TBL] [Abstract][Full Text] [Related]
4. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
7. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer.
Lv W; Tan Y; Zhou X; Zhang Q; Zhang J; Wu Y
Front Immunol; 2022; 13():989928. PubMed ID: 36189319
[TBL] [Abstract][Full Text] [Related]
8. A signature based on 11 autophagy genes for prognosis prediction of colorectal cancer.
Chen S; Wang Y; Wang B; Zhang L; Su Y; Xu M; Zhang M
PLoS One; 2021; 16(10):e0258741. PubMed ID: 34699544
[TBL] [Abstract][Full Text] [Related]
9. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer.
Li X; Li J; Li J; Liu N; Zhuang L
BMC Genomics; 2024 Jan; 25(1):51. PubMed ID: 38212708
[TBL] [Abstract][Full Text] [Related]
11. An immune-related gene prognostic index for predicting prognosis in patients with colorectal cancer.
Li C; Wirth U; Schardey J; Ehrlich-Treuenstätt VV; Bazhin AV; Werner J; Kühn F
Front Immunol; 2023; 14():1156488. PubMed ID: 37483596
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
13. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
14. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes.
Yang X; Wei Q
Immunobiology; 2023 Mar; 228(2):152352. PubMed ID: 36827833
[TBL] [Abstract][Full Text] [Related]
16. A five-immune-related genes-based prognostic signature for colorectal cancer.
Zhu L; Wang H; Wang Z
Int Immunopharmacol; 2020 Nov; 88():106866. PubMed ID: 32781411
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.
Hou Y; Zhang R; Zong J; Wang W; Zhou M; Yan Z; Li T; Gan W; Lv S; Zeng Z; Yang M
Front Immunol; 2022; 13():892512. PubMed ID: 35711437
[TBL] [Abstract][Full Text] [Related]
18. Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer.
Xiao Y; Zhang G; Wang L; Liang M
Front Endocrinol (Lausanne); 2022; 13():1069528. PubMed ID: 36518242
[TBL] [Abstract][Full Text] [Related]
19. Characterization of butyrate-metabolism in colorectal cancer to guide clinical treatment.
Luo Q; Zhou P; Chang S; Huang Z; Zeng X
Sci Rep; 2023 Mar; 13(1):5106. PubMed ID: 36991138
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a circular RNA regulatory stemness-related gene pair signature for predicting prognosis and therapeutic response in colorectal cancer.
Chen Q; Tang P; Huang H; Qiu X
Front Immunol; 2022; 13():934124. PubMed ID: 35958575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
